Take a look at the Optune publications
Unprecedented 5-year survival data for newly diagnosed glioblastoma from the EF-14 trial published in JAMA
Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.
Journal of the American Medical Association
Stupp R, Taillibert S, Kanner A, et al. 2017;318(23):2306-2316.
Copyright 2017 American Medical Association. All rights reserved.
2017 article from The ASCO Post on the unprecedented 5-year survival results seen with Optune + TMZ in EF-14
‘Out-of-the-box’ approach plus temozolomide extends survival in glioblastoma.
The ASCO Post
Goodman A. http://www.ascopost.com/issues/may-10-2017/out-of-the-box-approach-plus-temozolomide-extends-survival-in-glioblastoma. Updated May 10, 2017. Accessed October 7, 2022.
Interim analysis of the EF-14 trial: Pivotal phase 3 data for newly diagnosed glioblastoma published in JAMA
Maintenance therapy with Tumor-Treating Fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial.
Journal of the American Medical Association
Stupp R, Taillibert S, Kanner AA, et al. 2015;314(23):2535-2543.
Copyright 2015 American Medical Association. All rights reserved.
The EF-11 trial: Pivotal phase 3 data for recurrent glioblastoma published in the European Journal of Cancer
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
European Journal of Cancer
Stupp R, Wong ET, Kanner AA, et al. 2012;48(14):2192-2202.
Copyright 2012 Elsevier. All rights reserved.
Management of dermatologic adverse events
Prevention and management of dermatologic adverse events associated with Tumor Treating Fields in patients with glioblastoma.
Frontiers in Oncology
Lacouture ME, Anadkat MJ, Ballo MT, et al. 2020;10:1045. doi:10.3389/fonc.2020.01045
Copyright © 2020 Lacouture, Anadkat, Ballo, Iwamoto, Jeyapalan, La Rocca, Schwartz, Serventi and Glas.
Results from the NovoTAL™ System User Study
NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study.
World Journal of Surgical Oncology
Chaudhry A, Benson L, Varshaver M, et al. 2015;13:316. doi: 10.1186/s12957-015-0722-3
Learn more below
Indications for Use
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.
Important Safety Information
Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.
Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.
Warnings and Precautions
The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.
If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.
Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.
Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).
Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.